VYNE vs. IPA, FBIO, JAN, BCTX, THTX, APRE, PMN, CASI, LEXX, and CARA
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), JanOne (JAN), BriaCell Therapeutics (BCTX), Theratechnologies (THTX), Aprea Therapeutics (APRE), ProMIS Neurosciences (PMN), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical preparations" industry.
VYNE Therapeutics (NASDAQ:VYNE) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings.
ImmunoPrecise Antibodies has a net margin of -60.23% compared to VYNE Therapeutics' net margin of -6,710.38%. ImmunoPrecise Antibodies' return on equity of -26.54% beat VYNE Therapeutics' return on equity.
VYNE Therapeutics currently has a consensus price target of $7.38, indicating a potential upside of 217.89%. ImmunoPrecise Antibodies has a consensus price target of $7.00, indicating a potential upside of 473.77%. Given ImmunoPrecise Antibodies' higher probable upside, analysts clearly believe ImmunoPrecise Antibodies is more favorable than VYNE Therapeutics.
VYNE Therapeutics received 16 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 57.50% of users gave VYNE Therapeutics an outperform vote.
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 1.8% of VYNE Therapeutics shares are held by company insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ImmunoPrecise Antibodies has higher revenue and earnings than VYNE Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, VYNE Therapeutics' average media sentiment score of 0.00 equaled ImmunoPrecise Antibodies'average media sentiment score.
VYNE Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, ImmunoPrecise Antibodies has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.
Summary
ImmunoPrecise Antibodies beats VYNE Therapeutics on 10 of the 15 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
